53 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
(PNH) in the United States, European Union, and other countries globally. The therapy is also under investigation for several other rare diseases
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
8 Jan 24
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
9:07am
for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries globally. The therapy is also under
8-K
EX-1.1
ylt2zc
1 Nov 23
Entry into a Material Definitive Agreement
7:59am
424B5
fabew0vvnn4h8s mi
1 Nov 23
Prospectus supplement for primary offering
7:51am
8-K
EX-99.1
n7w rkyxq864
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
8-K
EX-1.1
pdf0oywgkxp7jn8kduaj
24 Mar 22
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8:18pm
424B5
o3c8m1 jyt1ehh2g
24 Mar 22
Prospectus supplement for primary offering
8:02pm
424B5
ry4z9yz6c18jy5h58988
23 Mar 22
Prospectus supplement for primary offering
5:14pm
8-K
EX-1.1
yj43cvo9 jbpf3ab967y
20 Jan 22
Entry into a Material Definitive Agreement
4:55pm